Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

capecitabine and docetaxel plus epirubicin for patients with HER2- breast cancer. They found that docetaxel plus capecitabine and docetaxel plus epirubicin had similar survival benefits and efficacy. In patients who received docetaxel plus capecitabine, there was a reduced incidence of neutropenia but a higher likelihood of hand-foot syndrome than that observed in the docetaxel plus epirubicin group.